ClinicalTrials.gg
CompletedNCT03760991ARTEMIS-DMUpdated Apr 25, 2022

Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin

A Phase 4 interventional study of INSULIN GLARGINE (U300) in Type 2 Diabetes Mellitus, sponsored by Sanofi. Completed at 14 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-25.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
372
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
64th of 175
372 · median 253
Started
2018
with 6 others
Phase 4
103 of 176
2 open now
Registered
149th of 176
by date
Lead sponsor
82 of 176
Sanofi

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 64th largest by enrollment of the 175 interventional ones that give a count, is one of 7 that started in 2018, is one of 103 in phase 4, and was the 149th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Primary Objective:

To assess the efficacy of Gla-300 on glycemic control measured by hemoglobin A1c (HbA1c) change in patients with type 2 diabetes mellitus (T2DM) uncontrolled with their current basal insulin following the switch to Gla-300.

Secondary Objectives:

To evaluate the effects of Gla-300 on glycemic control, treatment satisfaction, and health care resource utilization (HCRU) outcomes.

To evaluate the safety of Gla-300.

Read the detailed description

Study duration per participant is approximately 29 weeks including a screening period of up to 2 weeks, a 26-week treatment period, and a post treatment follow-up phone call visit at Week 27.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with type 2 diabetes mellitus.
  • Participants on "standard of care" basal insulin therapy administered once or twice daily, as per labeling for at least 6 months prior to screening visit, with or without other antidiabetics approved for using with insulin.
  • (HbA1c) between 7.5% (58 mmol/mol) and 10% (86 mmol/mol) inclusive, during screening.
  • Fasting plasma glucose values above 130 mg/dL.

Exclusion criteria

Exclusion criteria:

  • Unstable basal insulin regimen in the last 8 weeks prior to screening visit (ie, type of insulin and time/frequency of the injection, insulin doses [variation more than ±20%]).
  • Treatment with insulin other than basal insulin: mixed insulin (premixes), rapid insulin, fast acting insulin analogues in the last 6 months before screening visit (use ≤10 days in relation to hospitalization or an acute illness is accepted).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
372 participants (actual)

Study arms

  • Experimental
    Insulin glargine (U300)

    Insulin glargine (U300) (Gla-300) once daily for 26 weeks on top of any other antidiabetic treatment except other basal insulin

    Drug: INSULIN GLARGINE (U300)

Interventions

  • Pharmaceutical form: Solution for injection in a prefilled pen Route of administration: Subcutaneous

    Also known as: HOE901, Toujeo, Gla-300

06

What researchers measure

Primary outcomes

  1. Change in glycated hemoglobin (HbA1c)

    Absolute change in HbA1c

    Time frame: Baseline to Week 26

Secondary outcomes

  1. Change in glycated hemoglobin (HbA1c)

    Absolute change in HbA1c

    Time frame: Baseline to Week 12

  2. Participants with HbA1c below 7%

    Percentage of participants with HbA1c below 7%

    Time frame: Week 12 and 26

  3. Participants with fasting self-monitored plasma glucose (SMPG) of 80 to 110 mg/dL (4.4 to 7.2 mmol/L)

    Percentage of participants reaching targeted fasting SMPG of 80 to 110 mg/dL (4.4 to 7.2 mmol/L)

    Time frame: Week 12 and 26

  4. Change in fasting SMPG

    Absolute change in fasting SMPG

    Time frame: Baseline to Week 26

  5. Change in SMPG profile

    Absolute change in SMPG profile

    Time frame: Baseline to Week 26

  6. Change in fasting plasma glucose (FPG)

    Absolute change in FPG

    Time frame: Baseline to Week 26

  7. Percentage of participants requiring rescue therapy

    Percentage of participants requiring rescue therapy by additional antidiabetic medication

    Time frame: Baseline to Week 12 and 26

  8. Number of participants with hypoglycemia events

    Number of participants with at least 1 hypoglycemia event

    Time frame: Baseline to Week 26

  9. Number of participants with adverse events (AEs)

    Number of participants with AEs, serious adverse events (SAEs) (including hypoglycemic episodes associated with seizures, coma, or unconsciousness).

    Time frame: Baseline to Week 27

  10. Change in Treatment satisfaction

    Change in treatment satisfaction as measured by insulin treatment satisfaction questionnaire

    Time frame: Baseline to Week 26

  11. Number of participants with health care utilization

    Number of participants with health care utilization, including hospitalization, emergency room visits, and office \[or specialty\] visits

    Time frame: Baseline to Week 26

07

Study locations

14 sites
  • Investigational site Argentina
    Buenos Aires, Argentina
  • investigational site COLOMBIA
    Colombia, Colombia
  • investigational site Egypt
    Egypt, Egypt
  • investigational site HONG KONG
    Hong Kong, Hong Kong
  • investigational site INDIA
    India, India
  • Investigational site Indonesia
    Indonesia, Indonesia
  • investigational site LEBANON
    Lebanon, Lebanon
  • Investigational site Malaysia
    Putrajaya, Malaysia
  • Investigational site PERU
    Peru, Peru
  • investigational site PHILIPPINES
    Philippines, Philippines
  • Investigational site Saudi Arabia
    Saudi Arabia, Saudi Arabia
  • Investigational site South Africa
    South Africa, South Africa
  • Investigational site Thailand
    Thailand, Thailand
  • investigational site TURKEY
    Turkey, Turkey
08

References and documents

Publications

  • Sethi B, Al-Rubeaan K, Unubol M, Mabunay MA, Berthou B, Pilorget V, Vethakkan SR, Frechtel G. Efficacy and Safety of Insulin Glargine 300 U/mL in People with Type 2 Diabetes Uncontrolled on Basal Insulin: The 26-Week Interventional, Single-Arm ARTEMIS-DM Study. Diabetes Ther. 2022 Jun 17:1-14. doi: 10.1007/s13300-022-01271-7. Online ahead of print. PubMed 35730004 ↗
  • Sethi B, Al-Rubeaan K, Unubol M, Mabunay MA, Berthou B, Pilorget V, Vethakkan SR, Frechtel G. Efficacy and Safety of Insulin Glargine 300 U/mL in People with Type 2 Diabetes Uncontrolled on Basal Insulin: The 26-Week Interventional, Single-Arm ARTEMIS-DM Study. Diabetes Ther. 2022 Jul;13(7):1395-1408. doi: 10.1007/s13300-022-01271-7. Epub 2022 Jun 17. PubMed 35713873 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Sep 2020, 21 months.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 21 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2018
First posted
Dec 3, 2018
StartActual
Dec 18, 2018
Primary completionActual
Sep 23, 2020
CompletionActual
Sep 23, 2020
Last update
Apr 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03760991
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 3, 2018
Start date
Dec 18, 2018
Primary completion
Sep 23, 2020
Completion
Sep 23, 2020
Last update
Apr 25, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion